- Home
- VCEL vs XENE Comparison
VCEL vs XENE Comparison
Compare VCEL & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCEL
- XENE
- Stock Information
- Founded
- VCEL 1989
- XENE 1996
- Country
- VCEL United States
- XENE Canada
- Employees
- VCEL N/A
- XENE N/A
- Industry
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- VCEL Health Care
- XENE Health Care
- Exchange
- VCEL Nasdaq
- XENE Nasdaq
- Market Cap
- VCEL 2.1B
- XENE 2.4B
- IPO Year
- VCEL 1997
- XENE 2014
- Fundamental
- Price
- VCEL $40.15
- XENE $33.18
- Analyst Decision
- VCEL Strong Buy
- XENE Strong Buy
- Analyst Count
- VCEL 8
- XENE 11
- Target Price
- VCEL $62.00
- XENE $54.82
- AVG Volume (30 Days)
- VCEL 430.8K
- XENE 1.5M
- Earning Date
- VCEL 07-31-2025
- XENE 08-07-2025
- Dividend Yield
- VCEL N/A
- XENE N/A
- EPS Growth
- VCEL 521.85
- XENE N/A
- EPS
- VCEL 0.05
- XENE N/A
- Revenue
- VCEL $238,541,000.00
- XENE $7,500,000.00
- Revenue This Year
- VCEL $23.03
- XENE N/A
- Revenue Next Year
- VCEL $24.52
- XENE $253.71
- P/E Ratio
- VCEL $705.61
- XENE N/A
- Revenue Growth
- VCEL 14.80
- XENE N/A
- 52 Week Low
- VCEL $37.39
- XENE $26.74
- 52 Week High
- VCEL $63.00
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- VCEL 44.33
- XENE 57.79
- Support Level
- VCEL $40.53
- XENE $31.09
- Resistance Level
- VCEL $43.57
- XENE $32.99
- Average True Range (ATR)
- VCEL 1.62
- XENE 1.21
- MACD
- VCEL -0.16
- XENE 0.20
- Stochastic Oscillator
- VCEL 28.65
- XENE 79.20
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.